返回 A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® CardioFlow Attends 2017 PCR London Valves

[2017-10-26] 

London, the UK – On September 24, MicroPort Shanghai CardioFlow Medtech Co., Ltd. ("MicroPort® CardioFlow") attended the PCR London Valves to display its in-house developed VitaFlow™ Transcatheter Aortic Valve and Delivery System ("VitaFlow™"). PCR London Valves is the world's largest educational meeting focused on the care of patients with valvular heart disease and specifically addressing percutaneous valve interventions. More than 3,000 experts and scholars from over 60 countries attended the congress.
 
During the "Innovators Day" on the first day, the representative of MicroPort® CardioFlow delivered a speech of "the Engineering Challenges in Bicuspid Aortic Valves" in the session of "TAVI Unfinished Business." The report contained two parts – the first part analyzed the engineering challenges of TAVI products in treating bicuspid aortic valve patients from five angles including incomplete valve expansion, paravalvular leak, annulus rupture, instable valve deployment and long-term durability of the valve. The second part combined engineering science with the clinical needs of bicuspid aortic valve patients to demonstrate the excellent efficacy of VitaFlow™ in the treatment of bicuspid aortic valve, due to its innovative valve design that can effectively reduce the paravalvular leak.
 
In the session of "TAVI in Bicuspid Aortic Valve Disease" on the third day, Professor Nicola Piazza of McGill University Health Center in Canada and Professor Darren Mylotte of University Hospital and National University of Ireland, Galway, respectively delivered speeches of "Defining the Issues – Pre-Procedural Imaging" and "Defining the Issues – Valve Implantation". They shared their clinical experience in using VitaFlow™ to treat patients with bicuspid aortic valve in terms of pre-procedural imaging analysis and valve implantation, which attracted wide attention from the audience. Other renowned cardiologists including Thomas Modine of Lille University Hospital in France and Professor Mao Chen of West China Hospital of Sichuan University also spoke highly of the excellent performance of VitaFlow™ in treating patients with bicuspid aortic valve and heavily calcified leaflet. Since VitaFlow™ was mentioned so many times, some experts called it "MicroPort® Session."
 
During the congress, several well-known cardiologists, including Bernard Prendergas of St Thomas' Hospital, Stephan Windecker of Bern University Hospital, Professor Mao Chen and Professor Yuan Feng of West China Hospital of Sichuan University, Professor Ruiyan Zhang of Ruijin Hospital of Shanghai Jiao Tong University, Christoph Naber of Contilia Heart and Vascular Center in Essen of Germany, as well as Didier Tchétché, Nicola Piazza, Thomas Modine, and Darren Mylotte of of Clinique Pasteur in Toulouse of France, visited MicroPort® CardioFlow booth and tried out VitaFlow™ II Transcatheter Aortic Valve and Delivery System. They highly recognized VitaFlow™'s efficacy in treating bicuspid aortic valve and the innovative designs of its delivery system such as motorized handle and omnidirectional navigation. Many of them said they looked forward to the market launch of VitaFlow™ to benefit more patients. VitaFlow™ has completed one-year clinical follow-up in China and it is expected that the excellent outcome of clinical trials in China will lay a solid foundation for the clinical studies of VitaFlow™ II in China and Europe in 2018. In August 2016, VitaFlow™ was granted the Green-Path by the China Food and Drug Administration ("CFDA"), a special fast-track procedure for innovative medical devices to gain CFDA approval, and is expected to gain CFDA approval in 2018.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:MicroPort® Angiography Guidewire Obtains CFDA Registration Certificate
[Next]:Canadian Orthopedic Expert Professor Paul Beaule Visits MicroPort® Orthopedics for Academic Exchange